LLY compared with TBPH: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

TBPHTheravance Biopharma, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

TBPHTheravance Biopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

TBPH

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▼−0.12%×0.02

May 7 '26±10.3%▲+0.47%×0.05

= impliedLLY realized, solidTBPH realized, hatchedOne scale, both sides: full bar = 25%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.0%

▲+1.30%

×0.11

Q3 FY25±24.6%▲+22.68%×0.92

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

TBPHTheravance Biopharma, Inc.

17.03▲+0.02%· post 17.04

ClosedNov 6 '26

Mkt cap$884.2MRevenue$21MQ2 FY26Revenue$107MFY25

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

TBPHTheravance Biopharma, Inc.

1,360.90▼−0.28%post 1,358.90

Price

17.03▲+0.02%post 17.04

$1.2T

Mkt cap

$884.2M

Q3 FY26$24.4B

Revenue

$21MQ2 FY26

FY25$65.2B

Revenue

$107MFY25

LLY1,360.90▼−0.28%vsTBPH17.03▲+0.02%ClosedNov 6 '26